Aussie Court Takes Testimony in Genetic Tech Gene-Patenting Case
This article was originally published in PharmAsia News
Executive Summary
An Australian court is taking testimony in the nation’s first case of a challenge to the practice of patenting human genetic material, this one claimed by U.S. biotech Myriad Genetics, which gained a 1994 patent for its BRCA1 mutation.